Elgan Pharma is a late-stage neonatology-focused biotechnology company, dedicated to developing therapies for preterm infants and other neonatal indications.
Premature births are the number one cause of newborn deaths worldwide, with over a million preterm babies dying each year. As the standard of care improves, survival rates of premature infants are increasing and today babies born as early as 24 weeks gestational age are likely to survive in developed countries. However, there are many short- and long-term prematurity associated complications, with the youngest babies at highest risk to suffer a serious and often life-threatening event that can lead to lifelong disabilities. There is a great need for solutions that improve health outcomes and quality of life of these babies and their families. Premature births also come with a high financial cost. While they comprise about 12% of all births, they are responsible for 60% of birth associated costs, amounting to over 26 billion USD annually in the US alone.
Elgan Pharma has two leading clinical programs- ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date.
ELGN-GI promotes a faster maturation of the infants' intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition, while minimizing serious complications and reducing burden and costs for healthcare systems. The product completed several clinical trials including a successful phase III and is currently starting a second phase III.
ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP)-a condition that occurs because of underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. Phase I study with the product was successfully concluded and phase II is currently launching.
Elgan Pharma was founded in 2018 and is based in Israel.